Clinical trial
A Prospective, Phase II, Multicenter Clinical Study of Pirtobrutinib Combined With Sonrotoclax Regimen in the Treatment of B-Cell Lymphoma
NCT07744750 is registered in ClinicalTrials.gov with Changzhou No.2 People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Phase II, Multicenter Clinical Study of Pirtobrutinib Combined With Sonrotoclax Regimen in the Treatment of B-Cell Lymphoma
- Lead sponsor
- Changzhou No.2 People's Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- August 30, 2026
- Completion date
- August 31, 2029
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cll / sll, dlbcl - diffuse large b cell lymphoma, mzl, richter transformation